Evidence map›Paper›PMID 38258087›Full record

ArticlePharmaceutics2024

Material-Sparing Feasibility Screening for Hot Melt Extrusion.

Amanda Pluntze, Scott Beecher, Maria Anderson, Dillon Wright, Deanna Mudie

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amanda PluntzeGlobal Research and Development, Small Molecules, Lonza, 64550 Research Road, Bend, OR 97703, USA.ORCID 0000-0002-6247-4645
Scott BeecherGlobal Research and Development, Small Molecules, Lonza, 64550 Research Road, Bend, OR 97703, USA.
Maria AndersonGlobal Research and Development, Small Molecules, Lonza, 64550 Research Road, Bend, OR 97703, USA.
Dillon WrightGlobal Research and Development, Small Molecules, Lonza, 64550 Research Road, Bend, OR 97703, USA.
Deanna MudieGlobal Research and Development, Small Molecules, Lonza, 64550 Research Road, Bend, OR 97703, USA.ORCID 0000-0002-3586-5069
Lonza (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hot melt extrusion (HME) offers a high-throughput process to manufacture amorphous solid dispersions. A variety of experimental and model-based approaches exist to predict API solubility in polymer melts, but these methods are typically aimed at determining the thermodynamic solubility and do not take into account kinetics of dissolution or the associated degradation of the API during thermal processing, both of which are critical considerations in generating a successful amorphous solid dispersion by HME. This work aims to develop a material-sparing approach for screening manufacturability of a given pharmaceutical API by HME using physically relevant time, temperature, and shear. Piroxicam, ritonavir, and phenytoin were used as model APIs with PVP VA64 as the dispersion polymer. We present a screening flowchart, aided by a simple custom device, that allows rapid formulation screening to predict both achievable API loadings and expected degradation from an HME process. This method has good correlation to processing with a micro compounder, a common HME screening industry standard, but only requires 200 mg of API or less.

Indexed as

copovidonefeasibilityhot melt extrusionmaterial sparing

Identifiers

PMID38258087
PMCPMC10819182
OpenAlexW4390614110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.